Cingulate Inc (CING)
NASDAQ:CING
Top Page
Cingulate Inc
(NASDAQ:CING)
Select Model
Select Model
Rating:44Neutral
Price Target:
$6.00
▼(-0.17% Downside)
Action:ReiteratedDate:04/03/26
The score is primarily pressured by weak financial performance (no revenue, widening losses, and ongoing cash burn with reliance on external financing). Technicals are also soft with the stock below key short-term averages and negative MACD. Corporate events provide some liquidity support via new financing access, but dilution risk tempers the benefit, while valuation is difficult to assess given negative earnings.
Positive Factors
Proprietary drug‑delivery technology and ADHD pipeline
Cingulate’s core business centers on a controlled‑release drug‑delivery platform with lead ADHD candidates CTX‑1301 and CTX‑1302. A differentiated delivery technology and focused CNS pipeline provide durable product differentiation and clear regulatory/commercial pathways if clinical success is achieved.
Negative Factors
No revenue with widening net losses
As a pre‑commercial biotech, Cingulate reports no product revenue and growing annual net losses. Persistent operating deficits limit internal funding capacity, increase dependence on external capital, and create execution risk if future trials or approval timelines slip or additional financing becomes constrained.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary drug‑delivery technology and ADHD pipeline
Cingulate’s core business centers on a controlled‑release drug‑delivery platform with lead ADHD candidates CTX‑1301 and CTX‑1302. A differentiated delivery technology and focused CNS pipeline provide durable product differentiation and clear regulatory/commercial pathways if clinical success is achieved.
Read all positive factors
Cingulate Inc (CING) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$69.89M
Dividend YieldN/A
Average Volume (3M)190.99K
Price to Earnings (P/E)―
Beta (1Y)5.81
Revenue GrowthN/A
EPS Growth93.84%
CountryUS
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.96
Shares Outstanding11,628,613
10 Day Avg. Volume270,731
30 Day Avg. Volume190,985
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)9.40
Price to Sales (P/S)0.00
P/FCF Ratio-1.35
Enterprise Value/Market Cap0.46
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.66
Forecast
1Y Price Target
$11.00Price Target Upside83.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.7
Revenue Forecast (FY)N/A
Cingulate Inc Business Overview & Revenue Model
Company Description
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), wh...
How the Company Makes Money
null...
Cingulate Inc Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
15
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -540.89K | -653.09K | -582.92K | -621.99K | -808.44K |
| EBITDA | -19.40M | -14.89M | -22.95M | -17.05M | -19.87M |
| Net Income | -22.45M | -15.55M | -23.53M | -17.68M | -20.74M |
Balance Sheet | |||||
| Total Assets | 15.07M | 14.86M | 3.49M | 11.41M | 22.89M |
| Cash, Cash Equivalents and Short-Term Investments | 10.95M | 12.21M | 52.42K | 5.36M | 16.49M |
| Total Debt | 8.79M | 5.10M | 3.51M | 5.87M | 1.19M |
| Total Liabilities | 12.56M | 7.41M | 10.36M | 7.52M | 2.04M |
| Stockholders Equity | 2.51M | 7.46M | -6.87M | 3.88M | 20.84M |
Cash Flow | |||||
| Free Cash Flow | -17.41M | -18.66M | -15.26M | -16.04M | -11.25M |
| Operating Cash Flow | -17.25M | -18.45M | -15.03M | -15.88M | -10.43M |
| Investing Cash Flow | -162.00K | -211.80K | -224.10K | -152.65K | -814.74K |
| Financing Cash Flow | 16.15M | 30.82M | 9.95M | 4.90M | 26.54M |
Cingulate Inc Technical Analysis
Neutral
6.01
Price Trends
6.71
Negative
5.41
Positive
4.81
Positive
Market Momentum
-0.20
Positive
42.94
Neutral
12.61
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CING, the sentiment is Neutral. The current price of 6.01 is below the 20-day moving average (MA) of 7.50, below the 50-day MA of 6.71, and above the 200-day MA of 4.81, indicating a neutral trend. The MACD of -0.20 indicates Positive momentum. The RSI at 42.94 is Neutral, neither overbought nor oversold. The STOCH value of 12.61 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CING.
Cingulate Inc Risk Analysis
Cingulate Inc disclosed 77 risk factors in its most recent earnings report. Cingulate Inc reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cingulate Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $228.43M | 0.03 | -62.91% | ― | ― | 46.09% | |
47 Neutral | $5.49M | -0.94 | -226.28% | 10.27% | 9.46% | 96.85% | |
45 Neutral | $20.61M | -2.53 | -94.03% | ― | ― | 32.92% | |
44 Neutral | $69.89M | -1.05 | -602.02% | ― | ― | 93.84% | |
42 Neutral | $25.32M | -0.46 | -49.73% | ― | ― | -0.50% | |
40 Underperform | $4.67M | -0.54 | -1292.87% | ― | ― | 18.47% |
* Healthcare Sector Average
CING
Cingulate Inc
6.01
1.90
46.23%
BGMS
Bio Green Med Solution
0.99
-54.21
-98.20%
NNVC
NanoViricides
0.95
-0.19
-16.32%
ENLV
Enlivex
0.96
0.02
1.69%
FBLG
FibroBiologics, Inc.
1.33
-16.17
-92.40%
BOLD
Boundless Bio Inc.
1.13
-0.25
-18.12%
Cingulate Inc Corporate Events
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
Cingulate Adds Independent Director Jiang to Board Committees
Positive
Apr 2, 2026
On March 27, 2026, Cingulate Inc. appointed Zhanpeng “Frederick” Jiang to its Board of Directors as a Class I director, with a term running until the 2028 annual stockholders’ meeting, subject to standard conditions. The appointm...
Private Placements and FinancingRegulatory Filings and ComplianceShareholder Meetings
Cingulate Announces ATM Equity Program and Share Issuance
Positive
Mar 24, 2026
On March 24, 2026, Cingulate Inc. entered into an at-the-market sales agreement with A.G.P./Alliance Global Partners, allowing the company to issue and sell up to $100 million of common stock from time to time under an existing shelf registration....
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and Financing
Cingulate Secures $12 Million PIPE to Advance CTx-1301
Positive
Feb 17, 2026
On February 6, 2026, Cingulate Inc. issued 25,786 common shares at $6.16 each to a lender in exchange for a portion of outstanding debt, using an exemption from registration to strengthen its balance sheet by partially reducing liabilities through...
Business Operations and StrategyPrivate Placements and Financing
Cingulate Advances Capital Raise with Private Placement Financing
Positive
Feb 6, 2026
From January 6 to February 5, 2026, Cingulate Inc. issued multiple tranches of common stock to a lender in exchange for portions of outstanding debt, with share prices ranging from $4.35 to $6.01, as part of a series of unregistered, debt-for-equi...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Cingulate Announces Private Placement and New Preferred Stock
Positive
Jan 28, 2026
On January 27, 2026, Cingulate Inc. entered into a securities purchase agreement with a group of accredited investors, including certain company insiders, for a $12 million private placement comprising 2,147,471 common shares, 973 shares of Series...
Private Placements and FinancingRegulatory Filings and Compliance
Cingulate Expands At-The-Market Equity Offering Capacity
Neutral
Jan 15, 2026
On January 12, 2026, Cingulate Inc. increased the maximum aggregate offering price of common stock that can be issued under its at-the-market offering agreement with H.C. Wainwright Co., LLC, raising the cap from $23.5 million to $31.9 million. A...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.